Tradestie Institutional Equity Comparison Engine

SAX vs HCM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HCM Overall Edge

HCM Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to HUTCHMED (China) Limited American Depositary Shares (HCM) driven by superior Valuation, Growth & Margin, Options & Structure while SAX counters with relative strength in Momentum & Technical. Fundamentally, SAX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus HCM at N/M Forward P/E and -6.3% operating margin (+0.2% YoY). In options structure, SAX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against HCM sits in UNCLASSIFIED (73rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HCM
SAX N/M vs HCM N/M Fwd P/E
Growth & Margin Winner HCM
Op Margin N/A vs -6.3% ยท YoY N/A vs +0.2%
Momentum & Technical Winner SAX
1Y -0.9% vs -9.8% ยท 52W Pos 25% vs 53%
Options & Structure Winner HCM
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (73rd %ile IV)
SAX US Equity
SAX
Institutional Equity
$24.43
+0.37% 1D
Market Cap N/A
1M Return -2.28%
1Y Return -0.89%
Forward P/E N/M
Unified AI Score
52.0 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
HCM NASDAQ
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
$13.22
-1.71% 1D
Market Cap $2.3B
1M Return -7.42%
1Y Return -9.82%
Forward P/E N/M
Unified AI Score
38.1 / 100 SELL
Tech 31.0 Fund 44.0 Flow 50.0 Mom 56.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SAX -0.89% HCM -9.82% Spread: +7.37 pp (HCM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SAX TTM Op. Margin: N/A HCM TTM Op. Margin: -6.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SAX vs HCM. Trailing 12-month operating profitability (SAX N/A vs HCM -6.3%) and valuation multiples (SAX N/M vs HCM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SAX (2) vs HCM (7)
Institutional Metric SAX HCM Criterion Row Winner
Market Capitalization Scale N/A $2.3B Larger Scale HCM
Trailing P/E Ratio Valuation N/M 134.0x Lower Multiple HCM
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.2% Higher Growth HCM
Operating Margin (TTM) Profitability N/A -6.3% Higher Margin HCM
Net Profit Margin Profitability N/A 3.3% Higher Margin HCM
Return on Equity (ROE) Capital Efficiency N/A 1.5% Higher ROE HCM
52-Week Range Position Momentum 25% ($24โ€“$26) 53% ($10โ€“$16) Stronger Trend HCM
Beta / 30D Volatility Risk Regime 0.10ฮฒ ยท 8% Vol 0.64ฮฒ ยท 45% Vol Lower Realized Risk SAX
Unified Institutional Score Composite Signal 52.0 / 100 (HOLD) 38.1 / 100 (SELL) Higher Composite SAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SAX vs HCM Buy Guide
SAX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live SAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
HCM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 73rd %ile
IV Regime Elevated (60thโ€“80th %ile)
Live HCM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SAX nor HCM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.